TNYA Tenaya Therapeutics, Inc.

NEUTRAL Impact: 3/10 DEFA14A
Horizon immediate Filed Apr 16, 2026 Processed 1mo ago SEC 0001193125-26-158096
Proxy solicitation materials
Latest settled — T+20d ⚠ clustered
TNYA ▲ +28.51% at T+20d
NEUTRAL call ✓ call won +28.51% · α vs SPY +22.70% · entry $0.7470 → $0.9600
Next anchor: T+60d in 5w
Last close $0.6860 (close Jun 8) · -8.17% from $0.7470 entry
Entry anchored
Apr 16, 07:03 AM ET
via Databento tick
T+1d
+4.69%
call +4.69% · α +3.47%
$0.7820
settled 8w ago
T+5d
-8.43%
call -8.43% · α -9.42%
$0.6840
settled 7w ago
T+20d
+28.51%
call +28.51% · α +22.70%
$0.9600
settled 27d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

Tenaya Therapeutics is holding its annual shareholder meeting to elect three directors, ratify its auditor, and amend its equity incentive plan to increase shares by 3% and remove the 4 million share annual limit.

Actionable Insight

The vote on the equity incentive plan amendment is the most significant item, as increasing the share pool by 3% could lead to modest dilution. Traders should monitor the outcome of this vote and the company's future stock issuance activity.

Key Facts

  • Tenaya Therapeutics is holding its annual shareholder meeting on May 27, 2026.
  • The meeting agenda includes electing three Class II directors: Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen.
  • Shareholders will vote to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2026.
  • A proposal to amend and restate the 2021 Equity Incentive Plan to increase the number of shares reserved for issuance by approximately 3% of outstanding shares and remove the annual limit of 4 million shares.

Financial Impact

The proposed increase in shares reserved for issuance is approximately 3% of outstanding shares, but the exact dollar amount is not disclosed.

dilution

Risk Factors

  • The increase in the equity incentive plan could lead to shareholder dilution.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-158096
Document: 0001193125-26-158096-index-headers.html0001193125-26-158096
Document: 0001193125-26-158096-index.html0001193125-26-158096
Document: 0001193125-26-158096.txt0001193125-26-158096
9 reports for TNYA
Performance horizon
33% Hit rate 1 of 3 directional calls best @ T+5▲ +9.04%Mar 5, 2026
Filters
Rows
Reports for TNYA — sortable, filterable
Type Now
May 29, 2026
11d ago
8-K
NEUTRAL ★ 3/10
$0.8700 $0.7280▼ −16.32%▼ −13.57%$0.6860 (−21.15%)
May 19, 2026
21d ago
Insider Cluster
NEUTRAL ★ 2/10
$0.8080 $0.7920▼ −1.98%▼ −3.22%$0.6860 (−15.10%)
May 16, 2026
24d ago
ANALYST-UPGRADE
BULLISH ★ 1/10
$3.76 $3.30▼ −12.23%▼ −14.36%$0.6860 (−81.76%)
Apr 16, 2026
7w ago
ANALYST-UPGRADE
MIXED ★ 1/10
$0.7820 $0.6720▼ −14.07%▼ −14.62%$0.6860 (−12.28%)
Apr 16, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$0.7470 $0.6840▼ −8.43%▼ −9.42%$0.6860 (−8.17%)
Mar 11, 2026
12w ago
8-K
NEUTRAL ★ 4/10
$0.8930 $0.8040▼ −9.97%▼ −8.99%$0.6860 (−23.18%)
Mar 11, 2026
12w ago
Press Release
MIXED ★ 6/10
$0.8930 $0.8040▼ −9.97%▼ −8.99%$0.6860 (−23.18%)
Mar 9, 2026
13w ago
Press Release
BULLISH ★ 7/10
$0.9580 $0.8570▼ −10.54%▼ −9.19%$0.6860 (−28.39%)
Mar 5, 2026
13w ago
8-K
BULLISH ★ 8/10
$0.8190 $0.8930▲ +9.04%▲ +11.27%$0.6860 (−16.24%)
Showing 9 of 9

US Market Status

Market Closed — Opens in 7h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access